ECHELON-2 (NCT01777152), A randomized, double-blind, phase 3 study of brentuximab vedotin plus CHP vs CHOP in previously untreated patients with CD30-positive peripheral t-cell lymphoma: 5-year results
Authors
Zinzani, P. L.Illidge, Timothy M
Horwitz, S. M.
O'Connor, O. A.
Pro, B.
Iyer, S. P.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Morschhauser, F.
Domingo-Domenech, E.
Rossi, G.
Kim, W. S.
Feldman, T. A.
Menne, T.
Belada, D.
Illes, A.
Tobinai, K.
Tsukasaki, K.
Yeh, S. P.
Huttmann, A.
Savage, K. J.
Yuen, S.
Miao, H.
Bunn, V.
Fenton, K.
Fanale, M. A.
Puhlmann, M.
Trumper, L.
Affiliation
Institute of Hematology “Seràgnoli” University of Bologna;Issue Date
2021